Biogen (BIIB) and Eisai's Leqembi medicine has been approved to treat mild cognitive impairment in early stages of Alzheimer's disease, the European Commission said Tuesday.
The medicine is for use in patients who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain, the Commission said.
The approval makes Leqembi the first such medicine to be authorized in the EU, it added.
Biogen and Eisai did not immediately respond to MT Newswires' requests for comment.
Price: 117.13, Change: -2.13, Percent Change: -1.79
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。